The pediatric hydroxyurea phase III clinical trial (BABY HUG): Challenges of study design

Pediatric Blood and Cancer

Volumn 54, Issue 2, 2010, Pages 250-255

  Thompson, Bruce W ^a   Miller, Scott T ^b   Rogers, Zora R ^c   Rees, Renee C ^a   Ware, Russell E ^d   Waclawiw, Myron A ^e   Iyer, Rathi V ^f   Casella, James F ^g   Luchtman Jones, Lori ^h   Rana, Sohail ⁱ   Thornburg, Courtney D ^j   Kalpatthi, Ram V ^k   Barredo, Julio C ^l   Brown, R Clark ^m   Sarnaik, Sharada ⁿ   Howard, Thomas H ^o   Luck, Lori ^p   Wang, Winfred C ^d  

^a Clinical Trials & Surveys Corp   (United States)

^b KINGS COUNTY HOSPITAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

ⁱ HOWARD UNIVERSITY   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^l UNIVERSITY OF MIAMI   (United States)

^m EMORY UNIVERSITY   (United States)

ⁿ CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^o UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^p DREXEL UNIVERSITY   (United States)

more..

Author keywords

Clinical trial; Hydroxyurea; Infants; Sickle cell

Indexed keywords

HYDROXYUREA; PLACEBO;

ARTICLE; BRAIN FUNCTION; BRAIN INJURY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL ANEMIA; SPLEEN FUNCTION; SPLEEN INJURY; STROKE; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; DRUG MONITORING; ENDPOINT DETERMINATION; HUMANS; HYDROXYUREA; INFANT; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 74849091075     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22269     Document Type: Article

References (44)

1. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991;325: 11-16.
2. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest 2000;106:337-338.
3. Hebbel RP, Boogaerts MA, Eaton JW, et al. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med 1980;302:992-995.
4. Hebbel RP, Schwartz RS, Mohandas N. The adhesive sickle erythrocyte: Cause and consequence of abnormal interactions with endothelium, monocytes/macrophages and model membranes. Clin Haematol 1985;14:141-161.
5. Hebbel RP, Yamada O, Moldow CF, et al. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: Possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest 1980;65:154-160.
6. Stockman JA, Nigro MA, Mishkin MM, et al. Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med 1972;287: 846-849.
7. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007;21:37-47.
8. de Jong PE, Statius van Eps LW. Sickle cell nephropathy: New insights into its pathophysiology. Kidney Int 1985;27:711-717.
9. Pearson HA, Spencer RP, Cornelius EA. Functional asplenia in sickle-cell anemia. N Engl J Med 1969;281:923-926.
10. Statius van Eps LW, Schouten H, Haar Romeny-Wachter CC, et al. The relation between age and renal concentrating capacity in sickle cell disease and hemoglobin C disease. Clin Chim Acta 1970;27: 501-511.
11. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
12. Mason KP, Grandison Y, Hayes RJ, et al. Post-natal decline of fetal haemoglobin in homozygous sickle cell disease: Relationship to parenteral Hb F levels. Br J Haematol 1982;52:455-463.
13. Stevens MC, Hayes RJ, Vaidya S, et al. Fetal hemoglobin and clinical severity of homozygous sickle cell disease in early childhood. J Pediatr 1981;98:37-41.
14. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992;79:2555-2565.
15. Dover GJ, Humphries RK, Moore JG, et al. Hydroxyurea induction of hemoglobin F production in sickle cell disease: Relationship between cytotoxicity and F cell production. Blood 1986;67:735-738.
16. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-1322.
17. de Montalembert M, Belloy M, Bernaudin F, et al. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. J Pediatr Hematol Oncol 1997;19:313-318.
18. de Montalembert M, Davies SC. Is hydroxyurea leukemogenic in children with sickle cell disease? Blood 2001;98:2878-2879.
19. Ferster A, Tahriri P,Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001;97:3628-3632.
20. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 1996;88:1960-1964.
21. Hoppe C, Vichinsky E, Quirolo K, et al. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. J Pediatr Hematol Oncol 2000;22:330-334.
22. Jayabose S, Tugal O, Sandoval C, et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996;129:559-565.
23. Kinney TR, Helms RW,O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999;94:1550-1554.
24. Olivieri NF,Vichinsky EP. Hydroxyurea in children with sickle cell disease: Impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol 1998;20:26-31.
25. Scott JP, Hillery CA, Brown ER, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996;128:820-828.
26. Wang WC, Wynn LW, Rogers ZR, et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 2001;139:790-796.
27. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia-The HUSOFT extension study. Blood 2005;106:2269-2275.
28. Etteldorf JN, Tuttle AW, Clayton GW. Renal function studies in pediatrics. 1. Renal hemodynamics in children with sickle cell anemia. AMA Am J Dis Child 1952;83:185-191.
29. Wigfall DR,Ware RE, Burchinal MR, et al. Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. J Pediatr 2000;136:749-753.
30. Fitzhugh CD, Wigfall DR, Ware RE. Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer 2005;45:982-985.
31. Ohene-Frempong K. Stroke in sickle cell disease: Demographic, clinical, and therapeutic considerations. Semin Hematol 1991;28: 213-219.
32. Respiratory mechanics in infants: Physiologic evaluation in health and disease. American Thoracic Society/European Respiratory Society. Am Rev Respir Dis 1993;147:474-496.
33. Baraldi E, Filippone M. Passive respiratory mechanics to assess lung function in infants. Monaldi Arch Chest Dis 1994;49:83-85.
34. Chung EE, Dianzumba SB, Morais P, et al. Cardiac performance in children with homozygous sickle cell disease. J Am Coll Cardiol 1987;9:1038-1042.
35. Lester LA, Sodt PC, Hutcheon N, et al. Cardiac abnormalities in children with sickle cell anemia. Chest 1990;98:1169-1174.
36. Sarnaik S, Slovis TL, Corbett DP, et al. Incidence of cholelithiasis in sickle cell anemia using the ultrasonic gray-scale technique. J Pediatr 1980;96:1005-1008.
37. Webb DK, Darby JS, Dunn DT, et al. Gall stones in Jamaican children with homozygous sickle cell disease. Arch Dis Child 1989;64:693-696.
38. Pearson HA, Gallagher D, Chilcote R, et al. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics 1985;76: 392-397.
39. Harrod VL, Howard TA, Zimmerman SA, et al. Quantitative analysis of Howell-Jolly bodies in children with sickle cell disease. Exp Hematol 2007;35:179-183.
40. Guasch A, Cua M, Mitch WE. Early detection and the course of glomerular injury in patients with sickle cell anemia. Kidney Int 1996;49:786-791.
41. Tejani A, Phadke K, Adamson O, et al. Renal lesions in sickle cell nephropathy in children. Nephron 1985;39:352-355.
42. Lan KK, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659.
43. Easa D, Norris K, Hammatt Z, et al. The research subject advocate at minority Clinical Research Centers: An added resource for protection of human subjects. Ethn Dis 2005;15:S5-107-110.
44. Heeney MM, Whorton MR, Howard TA, et al. Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol 2004;26:179-184.